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The majority of myocardial protective techniques performed in the United 
States incorporate hypothermic, hyperkalemic blood or crystalloid cardiople- 
gia. Oxygenated blood cardioplegia has not been compared with oxygenated 
crystalloid cardioplegia in an isolated myocyte model of hypothermic, hy- 
perkalemic ardioplegic arrest in which direct measurements of contractile 
function and myocyte swelling can be made. Accordingly, isolated myocyte 
contractile function and myocyte profile surface area were examined after 
hypothermic arrest with oxygenated crystalloid or blood cardioplegia. Methods: 
Isolated left ventricular pig myocytes were randomly assigned to undergo 
cardioplegic arrest for 2 hours at 4 ° C. Either oxygenated crystalloid or blood 
cardioplegia was used. After 2 hours, myocytes were reperfused with standard 
cell medium at 37 ° C and contractile function was examined. A control group 
of myocytes was maintained in cell medium at 37°C for 2 hours. Myocyte 
velocity of shortening (micrometers p  econd) was examined at baseline and 
after 13-adrenergic stimulation (isoproterenol, 25 nmol/L). Velocity of shorten- 
ing declined equally from baseline control values (65 +- 2 ptm/sec) in the 
groups ubjected to oxygenated crystalloid cardioplegia and blood cardioplegia 
(37 - 2 pm/sec and 42 + 1 ptm/sec, respectively; p < 0.05). Results: Although 
13-adrenergic stimulation caused a significant increase in velocity of shortening 
in all myocyte groups, the increase was less pronounced in myocytes subjected 
to crystalloid cardioplegia (157 -+ 6 ptm/sec) and blood cardioplegia (159 + 6 
~m/sec) than in normothermic control myocytes (205 --. 7 pm/sec; p < 0.05). 
Myocyte profile surface area, an index of cell volume, was measured in all 
myocyte groups. Myocyte surface area increased equally after cardioplegic 
arrest and rewarming in both cardioplegia groups (crystalloid 4119 - 53/.tm2; 
blood 3924 - 48 ~m2); surface areas in both cardioplegia groups were 
significantly greater than in the normothermic control group (3158 - 39 pm 2, 
p < 0.05). Conclusion: Equivalent effects of oxygenated crystalloid and blood 
cardioplegia were observed with respect to myocyte contractile function, 
inotropic responsiveness, and intraceUular volume regulatory processes. 
(J Thorac Cardiovasc Surg 1996;112:1064-72) 
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C ardioplegic arrest during cardiac operations is 
typically accomplished by hyperkalemic solutions 
that cause rapid myocyte membrane depolarization 
and thereby uncouple excitation and contraction. 
Despite significant improvements in the delivery and 
composition of cardioplegic solutions over the past 
decade, left ventricular (LV) dysfunction and myo- 
cardial edema continue to complicate the postoper- 
ative course of some patients having cardiac opera- 
tions.1, 2 Although a number of different myocardial 
preservation techniques in current practice limit 
ischemic injury during cardiac surgical procedures, 
the optimal cardioprotective strategy is still unclear. 
Research efforts have recently focused on compari- 
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sons between blood and oxygenated crystalloid car- 
dioplegic solutions. Randomized clinical studies and 
experimental preparations in vivo that have com- 
pared blood and oxygenated crystal!oid cardioplegic 
solutions have yielded mixed results with regard to 
the preservation of contractile function and myocar- 
dial edema. Proponents of blood cardioplegia claim 
superior protection from ischemic and reperfusion 
damage. They note improved ventricular function 
and reduced edema owing to enhanced oxygen- 
carrying capacity, endogenous free radical scaveng- 
ing, and improved onconicity, buffering, and rheo- 
logic effects. 3 Moreover, more than 70% of 
cardiothoracic surgeons currently use blood cardio- 
plegia. 4Other studies, however, have shown oxygen- 
ated crystalloid cardioplegia to be comparable with 
blood cardioplegia or even superior in preserving 
contractile function at lower temperatures, s-7
The changes in LV loading conditions, heart rate, 
and plasma catecholamine concentrations that oc- 
cur after cardioplegic arrest and rewarming make it 
difficult to determine direct effects of various car- 
dioplegic solutions on LV contractile function in 
clinical or whole-heart preparation studies. Exami- 
nation of contractile properties of isolated myocytes 
has certain distinct advantages over studies of in 
vivo preparations, including removal of loading con- 
ditions, absence of neurohormonal influences, and 
the capacity to directly examine contractile function 
without confounding effects from populations of 
nonmyocyte cells or alterations in coronary perfu- 
sion. Furthermore, the extracellular milieu can be 
precisely controlled so that specific and direct influ- 
ences of various cardioplegic solutions on contrac- 
tile function can be determined. Efforts to preserve 
contractile function and reduce myocardial edema 
after cardioplegic arrest have become increasingly 
important as the proportion of older, debilitated 
patients with more compromised LV function in the 
cardiac surgical population has increased. S Accord- 
ingly, the present study compares the direct effects 
of oxygenated crystalloid and blood cardioplegia on 
contractile function and volume regulation in an 
isolated myocyte model of hypothermic, hyperkale- 
mic cardioplegic arrest o better understand optimal 
cardioprotective strategies. 
Methods 
Myocyte isolation. Yorkshire swine (25 to 30 kg) were 
the source of myocytes for this study. All animals were 
treated and cared for in accordance with the "Guide for 
the Care and Use of Laboratory Animals" prepared by the 
Institute of Laboratory Animal Resources and published 
by the National Institutes of Health (NlH Publication No. 
86-23. revised 1985). Myocyte isolation was performed as 
previously described. 9 After the animal was anesthetized 
with 2% isoflurane in oxygen, a sternotomy was per- 
formed and the heart quickly extirpated and placed in 
oxygenated Krebs solution. The great vessels were rapidly 
removed at the aortic and pulmonary valves, and a region 
of the LV free wall incorporating the circumflex artery (5 
by 5 cml was excised and used for myocyte isolation. The 
left circumflex artery was cannulated, the distal branches 
were ligated, and the tissue was rinsed free of blood with 
35 ml of a modified Kraft-Bruhe solution (KC1. 80 
mmol/L; K2HPO~, 30 mmol/L: MgSO4, 5 mmol/L: glu- 
cose, 10 retool/L: Na2-adenosine triphosphate, 5 retool/L; 
taurine. 20 mmol/L; creatine. 5 mmol/L: succinate. 5 
mmol/L; and HEPES buffer. 5 mmol/L) supplemented 
with nitrilotriacetic acid (5 mmol/L) and 0.1% salt-free 
bovine serum albumin. Collagenase (0.5 mg, ml, Worth- 
ington type II: 146 U/mg/was then added to 75 ml of the 
modified Kraft-Bruhe solution and the tissue was perfused 
with the collagenase solution for 35 minutes. All perfusion 
procedures were performed at 37 ° C and perfusion solu- 
tions were continuously aerated with 95% oxygen and 5@ 
carbon dioxide. The tissue was then minced into 2 mm 
sections and added to an oxygenated titration solution of 
Kraft-Bruhe solution containing 2% bovine serum albu- 
min. deoxyribonuclease II (DNase, 51 Kunitz units per 
milliliter, type IV. Sigma Chemical Company, St Louis. 
Mo.), CaCI2 (300/,mol/L), and collagenase (0.5 mg/ml). 
The tissue and titration solution were transferred to a 
centrifuge tube and gently agitated. After 15 minutes, the 
supernatant was removed and filtered and the cells were 
allowed to settle. The myocyte pellet was then resus- 
pended in Dulbecco's modified Eagle's medium (Nutrient 
Mixture F-12. pH 7.4. Ca2 2.0 mmol/L. Gibco Laborato- 
ries. Grand Island. N.Y. ). The number of viable myocytes 
was counted at 100× magnification with a hemocytometer 
(Reichert-Jung, Leica, Inc.. Optical Products Div.. Buf- 
falo. N.Y.) and resuspended to a final concentration of
5 X 10 4 cells/ml. We 9 have previously shown that viable 
myocytes exclude trypan blue, maintain a rod shape, are 
calcium tolerant, respond to electrical stimulation, and 
are stable in culture. 
Myocyte contractile function and experimental design. 
An aliquot (2 ml) of the isolated myocyte suspension was 
placed on coverslips previously coated with a laminin 
fibronectin matrix (Matrigel, Collaborative Biomedical. 
Inc.. Bedford, Mass.) and incubated at 37 ° C for 1 hour. 
The myocytes were then placed in a thermostatically 
controlled chamber (37 ° C) and fitted for a coverstip for 
imaging on an inverted microscope {Axiovert IM35. Carl 
Zeiss. Oberkochen, Germaw). The volume of the cham- 
ber was 2.5 ml. and it contained two stimulating platinum 
electrodes and a mimature thermocouple (CN7100: 
Omega Engineering, Inc.. Stamford, Conn.). The medium 
within the chamber was oxygenated before entering a 
miniature pump system (733100 Reglo; Ismatec. Switzer- 
land), which changed the medium within the chamber 
every t5 minutes. The myocytes were imaged with a 20× 
long-working distance Hoffmann Modulation Contrast 
objective (Modulation Optics. Inc.. Greenvale, N.Y.) with 
10 6 6 Handy et al. 
The Journal of Thoracic and 
Cardiovascular Surgery 
October 1996 
a final magnification of 1100 ×. Myocyte contractions were 
elicited by field stimulating the tissue chamber at 1 Hz 
(S!I, Grass Instrument Co., West Warwick, R.I.) by 
means of current pulses of 5 msec duration and voltages 
10% above contraction threshold. 9 The polarity of the 
stimulating electrodes was alternated at every pulse to 
prevent the buildup of electrochemical by-products. Myo- 
cyte contractions were imaged with a charge-coupled 
device with a noninterlaced scan rate of 240 Hz (GPCD60, 
Panasonic Communications and Systems Div., Secaucus, 
N.J.). Myocyte motion signals were captured with the cell 
parallel to the video raster lines, and this video signal was 
input through an edge detector system (Crescent Elec- 
tronics, Sandy, Utah). The changes in light intensity at the 
myoeyte dges were used to track myocyte motion? The 
distance between the left and right myocyte dges was 
converted into a voltage signal, digitized, and input to a 
computer (80286; ZBV2526, Zenith Data Systems, St. 
Joseph, Mich.) for subsequent analysis. 
Stimulated myocytes were allowed a 5-minute stabiliza- 
tion period after electrical stimulation, and contraction 
data for each myocyte were recorded from a minimum of 
20 consecutive contractions. Parameters computed from 
the contraction profiles included myocyte resting length 
(micrometers), velocity of shortening (micrometers per 
second), and velocity of relengthening (micrometers per 
second). Myocyte percent shortening was determined as 
the percentage difference between maximum and mini- 
mum cell length for each contraction. Myocyte velocity 
computations were obtained by differentiating the digi- 
tized contraction profiles. These parameters were calcu- 
lated for each contraction and the results were averaged 
for 20 contractions. Digital data regarding myocyte length 
throughout contraction were graphically plotted on a time 
scale to make sequential analog contraction profiles. 
After collection of baseline myocyte contractile perfor- 
mance the myocytes were then randomly assigned to one 
of the following treatment protocols: normothermic con- 
trol--incubation in cell culture medium at 37°C for 2 
hours (n = 150); crystalloid cardioplegia--incubation with 
an oxygenated crystalloid cardioplegic solution (K + 24 
mEq, oxygen tension 300 __+ 25 mm Hg, pH 7.38 -+ 0.05, 
n = 140) and stored at 4 ° C for 2 hours; blood cardiople- 
g/a--incubation with an oxygenated blood cardi0plegic 
solution (80% tromethamine-buffered blood, hematocrit 
value 17% to 22%, K + 22 mEq, oxygen tension 280 + 20 
mm Hg, pH 7.52 _+ 0.03, n = 140) and stored at 4 ° C for 
2 hours. Because the blood cardioplegia protocol required 
continuous gentle agitation throughout the hypothermic 
incubation period to prevent erythrocytes from becoming 
attached to the laminin/fibronectin matrix and thus ob- 
scuring the myocytes, both cardioplegia protocols in- 
cluded continuous gentle agitation of the myocytes 
throughout he hypothermic incubation period. After 
treatment, he myocytes were transferred to the stimula- 
tion chamber and rewarmed with Oxygenated medium 
until the bath temperature turned to 37 ° C. Steady state 
contractile measurements were obtained as described in 
the previous ection. To define/3-adrenergic responsive- 
ness, contractile function of the myocytes from the three 
treatment protocols was then measured in isoproterenol, 
25 mmol/L. 
Isolated myocyte surface area. To determine the differ- 
ential effects of the individual cardioplegic solutions on 
myocyte volume regulatory processes, isolated profile 
surface area was measured in myocytes ubjected to the 
three treatment protocols outlined in the previous ection. 
It has been previously demonstrated that profile surface 
area directly reflects cell volume. 1° Isolated myocyte 
surfacd area was measured by means of methods previ- 
ously described by this laboratoryl 9 In brief, after normo- 
thermie incubation or cardioplegic arrest and rewarming, 
myocytes were immediately placed in a buffered sodium 
eac0dylate solution containing 2% paraformaldehyde and 
2% glutaraldehyde (pH 7.4, 325 mOsm/L). Preserved 
myocytes were examined on an inverted light microscope 
(IM-35, Carl Zeiss). Myocytes were imaged at 1000x 
magnification with an epifluorescence illuminator having 
a rhodamine filter. Isolated myocyte borders were digi- 
tized by means of an image analysis ystem (Zeiss/Kon- 
tron, IBAS), and profile surface area was computed by 
planimetry directly from the digitized image. 
Data analysis. Changes in indices of myocyte contrac- 
tile function between the control, crystalloid, and blood 
cardioplegia groups were examined by multivariate anal- 
ysis of variance. If the analysis of variance revealed 
significant differences, pairwise tests of individual group 
means were compared by means of Tukey's procedure. All 
statistical nalysis was performed with the use of standard 
statistical software programs (BMDP Statistical Software 
Inc., Los Angeles, Calif.). Results are presented as 
mean + standard error of the mean. Values of p < 0.05 
were considered tO be statistically significant. 
Results 
Myocyte contractile function. Steady state myo- 
cyte contractile function and representative myocyte 
contraction profiles for normothermic control, oxy- 
genated crystalloid cardioplegia , and blood cardio- 
plegia groups are summarized in Table I and Fig. 1. 
In agreement with prior reports, myocyte contractile 
function after 2 hours of normothermic ncubation 
was similar to baseline values obtained immediately 
after myocyte isolation. 11 Therefore only contractile 
function parameters after normothermic ncubation 
are reported. Contractile function of myocytes ex- 
posed to either crystalloid cardioplegia or blood 
cardioplegia followed by rewarming was significantly 
worse than that of control myocytes. Specifically, the 
velocity of shortening was reduced 43% in the 
crystalloid cardioplegia group and 35% in the blood 
cardi0Plegia group compared with control values. 
Percent shortening was reduced by 42% and 33% in 
the crystalloid and blood cardioplegia groups, re- 
spectively. The velocity of re!engthening, which is an 
index of active relaxation, was also significantly 
reduced by more than 40% in both cardioplegia 
groups. Thus, consistent with past studies, hypother- 
mic, hyperkalemic cardioplegic arrest caused a re- 
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duction in isolated myocyte contractile process. 9'21 
Moreover, cardioplegic arrest with both oxygenated 
crystalloid and blood cardioplegic solutions de- 
creased myocyte contractile function to a similar 
degree after rewarming. 
Myocyte 18-adrenergic responsiveness. Isoproter- 
enol (25 nmol/L) was added to normothermic con- 
trol, crystalloid cardioplegia, nd blood cardioplegia 
myocytes to compare the effects of crystalloid and 
blood cardioplegia on #-adrenergic responsiveness 
(see Table I). Measurements of myocyte contractile 
function in the presence of isoproterenol for the 
three treatment groups are also provided in Table I. 
Isoproterenol caused a significant increase in myo- 
cyte contractile function in normothermic control, 
crystalloid cardioplegia, and blood cardioplegia 
myocytes. Specifically, the velocity of shortening and 
percent shortening were increased by greater than 
100% over baseline values in all groups. However, 
contractile function indices of myocytes in either the 
crystalloid cardioplegia or blood cardioplegia 
groups after isoproterenol administration remained 
significantly ower than these indices for normother- 
mic control rnyocytes (Table I). Oxygenated crystal- 
loid cardioplegia nd blood cardioplegia reduced 
/3-adrenergic responsiveness equally. 
Myocyte profile surface area. To determine 
changes in myocyte volumes after cardioplegic ar- 
rest with oxygenated crystalloid or blood cardiople- 
gia, we measured myocyte profile surface area in 
normothermic control, crystalloid cardioplegia, nd 
blood cardioplegia myocytes. As illustrated in Fig. 2, 
myocyte profile surface area formed a Gaussian 
distribution in normothermic control myocytes with 
a mean value of 3158 _+ 39 /xm 2. Crystalloid and 
blood cardioplegia resulted in a similar and signifi- 
cant increase in myocyte profile surface area to 
4119 + 53 /xm 2 and 3924 ± 48 /xm 2, respectively 
(p < 0.05 vs control). 
Discussion 
Improved myocardial preservation during cardiac 
operations has remained a concern of cardiac sur- 
geons for decades. Despite significant improvement 
in cardioplegic techniques, transient LV dysfunction 
and myocardial edema still occur after cardioplegic 
arrest and rewarming. The composition and delivery 
methods of cardioplegic solutions have undergone 
extensive investigation tominimize this LV dysfunc- 
tion. 12 Recently, blood has been proposed as the 
most efficacious delivery vehicle for hyperkalemic 
cardioplegia to limit ischemic damage to myocardi- 
Table I 
lsoproterenol 
Baseline (25 nmot/L) 
Percent shortening (%) 
Normothermic controt 5.2 ± 
Blood cardioplegia 3.5 _+ 
Crystalloid cardioplegia 3.0 ± 
Velocity of shortening 0xm/sec) 
Normothermic control 65 _+ 
Blood cardioplegia 42 ± 
Crystalloid cardioplegia 37 ± 
Velocity of relengthening 0xm/sec) 
Normothermic control 70 ± 3 
Blood cardioplegia 40 ± 2* 
Crystalloid cardioplegia 36 +_ 2* 
No. of myocytes 
Normothermic control 150 
Blood cardioplegia 140 
Crystalloid cardioplegia 140 
0.1 11.2 _+ 0.2t 
0.1" 9.6 -+ 0.3*t 
0.1" 9.6 ± 0.2"~ 
2 205 ± 7t 
1' 159 ± 6*t 
2* 157 ± 6*t 
197 + 8t 
145 _+ 7"~ 
145 -+ 6"~ 
132 
119 
123 
*p < 0.05 versus normothermic control. 
tVersus baseline. 
urn. 12-14 The development of oxygenated crystalloid 
cardioplegic solutions also appears to represent a
significant advance in cardiac protection. 5'6' 15, 16 
The ability of these cardioplegic solutions to pre- 
serve contractile function and volume regulatory 
processes has not been compared in isolated myo- 
cytes. In the present study, isolated myocyte contrac- 
tile function and myocyte volume regulation were 
examined after hypothermic, hyperkalemic ar- 
dioplegic arrest with oxygenated crystalloid and 
blood cardioplegic solutions. The unique and signif- 
icant findings of the present study were as follows: 
(1) both oxygenated crystalloid cardioplegia nd 
blood cardioplegia caused a similar reduction in 
myocyte contractile function and /3-adrenergic re- 
sponsiveness and (2) both oxygenated crystalloid 
and blood cardioplegia resulted in a similar disrup- 
tion of myocyte volume regulation. 
Blood cardioplegia emerged in the 1980s, imme- 
diately gained popularity, and is currently the most 
widely used mode of cardioplegia. 4 Proponents of 
blood cardioplegia cite several theoretical advan- 
tages of the blood vehicle: (1) a reduction in sys- 
temic hemodilution, (2) improved onconicity and 
buffering because of the presence of blood proteins, 
(3) rheologic benefits on the microvasculature, (4)
oxygen-derived free radical scavenging resulting 
from superoxide dismutase and catalase, and (5) 
improved oxygen-carrying capacity. ~2' 17 Such poten- 
tial benefits would be expected to reduce myocardial 
damage during cardioplegic arrest and thereby re- 
sult in improved preservation ofcontractile function 
1068 Handy et aL 
The Journal of Thoracic and 
Cardiovascular Surgery 
October 1996 
(D 
4e.a 
Q 
140 
138 
136 
134 
132 
130 
140 
138 
136 
134 
132 
130 
140 
138 
136 
134 
132 
130 
Normothermia  
U-27 
I I 
Crystal loid Cardioplegia 
B lood Cardioplegia 
I I 1 
1 2 3 
Time (s) 
Fig. 1. Representative contractile profiles of normothermic (control) myocytes and myocytes exposed to 
hypothermic cardioplegic arrest with either oxygenated crystalloid or blood cardioplegia. Myocyte 
contractile profiles were measured after ewarming during field stimulation at 1 Hz. A significant and equal 
depression i  the extent of shortening was observed after hypothermic cardioplegic arrest with both 
oxygenated crystalloid cardioplegia nd blood cardioplegia. Please see Table I for summary results. 
after rewarming. However, experimental nd clini- 
cal studies comparing the preservation of contractile 
function after cardioplegic arrest between blood 
cardioplegia and oxygenated crystalloid cardioplegia 
have yielded mixed, equivocal results. Both car- 
dioplegic solutions result in excellent cardiac pro- 
tection and appear to preserve contractile function 
better than nonoxygenated solutions) 4-16' 18, 19 At 
infusion temperatures of 20°C or greater or with 
reperfusion of acutely ischemic myocardium, blood 
cardioplegia ppears to provide superior results, z° 
However, at lower infusion temperatures blood car- 
dioplegia and oxygenated crystalloid cardioplegia 
appear to provide similar preservation of contractile 
function and recovery of high-energy phosphates, 
provided that a low-sodium crystalloid solution is 
not used. s' as, 16 Moreover, at 4 ° C, oxygenated crys- 
talloid cardioplegia has been shown to result in 
improved recovery of ventricular function as deter- 
mined by end-systolic pressure-length relation- 
ships. 6 In the current study, there was no difference 
in the preservation of contractile function between 
isolated myocytes after cardioplegic arrest with 
blood or oxygenated crystalloid cardioplegia. The 
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Fig. 2. Myocyte profile surface area for normothermic ( ontrol) myocytes and for myocytes after 
hypothermic cardioplegic arrest with oxygenated crystalloid cardioplegia nd blood cardioplegia. The 
number of myocytes measured is indicated on the Yaxis. Myocyte profile surface area formed a Gaussian 
distribution. A significant and equal increase in profile surface area was observed for myocytes that 
underwent hypothermic cardioplegic arrest and rewarming with oxygenated crystalloid cardioplegia nd 
blood cardioplegia. Please see Results for summary statistics. 
reduction in myocyte contractile function after car- 
dioplegic arrest and rcwarming was similar in the 
two experimental groups. This reduction in myocyte 
contractile function after cardioplegic arrest and 
rewarming provides a cellular basis for the reduced 
LV function observed clinically and in isolated heart 
preparations after hyperkalemic cardioplegic arrest. 
It further suggests that at 4 ° C, there are no advan- 
tages to blood cardioplegia relative to oxygenated 
crystalloid cardioplegia in the preservation of iso- 
lated myocyte contractile function. However, incu- 
bation temperatures at 4 ° C for cardioplegic arrest 
would tend to favor oxygenated crystalloid car- 
dioplegic solutions. Magovern and colleagues 21
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demonstrated better preservation of isovolumic de- 
veloped LV pressure with blood cardioplegia than 
with crystalloid cardioplegia t 20 ° C, but at 10 ° C or 
4 ° C crystalloid solutions provided better myocardial 
protection. Progressive hypothermia shifts the oxy- 
gen-hemoglobin dissociation curve to the left, which 
reduces release of oxygen from blood cardioplegic 
solutions. In contrast, all of the oxygen carried by a 
crystalloid solution is available for release because 
of its linear oxygen dissociation curve. I5 Moreover, 
the solubility of oxygen in crystalloid solutions in- 
creases as the temperature decreases. At 10 ° C, 
therefore, an oxygenated crystalloid cardioplegic 
solution has more oxygen available for release than 
arterial whole blood, oxygenated pump perfusate, or 
an oxygenated blood cardioplegic solution. 22 Future 
studies that more carefully examine temperature- 
dependent differences in cardioplegic techniques on 
myocyte contractile function would be appropriate. 
A frequent consequence ofhypothermic, hyperkale- 
mic cardioplegic arrest is myocardial edema. 2'23 
Myocardial water content significantly increases af- 
ter cardioplegic arrest and reperfusion; this increase 
is directly associated with a reduction in LV com- 
pliance and contributes to a subsequent deteriora- 
tion in LV performance. 2' 24 Moreover, myocardial 
edema may limit coronary perfusion during reoxy- 
genationY In the current study, hyperkalemic car- 
dioplegic arrest with both oxygenated crystalloid 
cardioplegia nd blood cardioplegia resulted in sim- 
ilar and significant increases in isolated myocyte 
profile surface area. Because surface area is directly 
proportional to myocyte volume, the increase in 
myocyte profile surface area after cardioplegic ar- 
rest represents cellular swelling. I° These results 
suggest hat similar alterations in myocyte volume 
regulatory processes occur after hyperkalemic car- 
dioplegic arrest with either oxygenated crystalloid or 
oxygenated blood cardioplegia. Prior reports have 
also shown no significant difference in the extent of 
myocardial edema after cardioplegic arrest with 
either blood or crystalloid cardioplegia in experi- 
mental heart preparations. 26'27 A significant in- 
crease in myocardial water content, however, has 
been shown after cardioplegic arrest with nonoxy- 
genated cardioplegic solutions compared with oxy- 
genated cardioplegic solutions, irrespective of the 
cardioplegic vehicle used. This observation further 
confirms the critical importance of oxygen in cardio- 
plegia.lS, 18 Oxygenation of cardioplegic solutions 
may preserve high-energy phosphates, which can 
limit acute changes in myocardial capillary mem- 
brahe integrity that may contribute to increases in 
myocardial edema. I8 Moreover, the extracellular 
hyperkalemia associated with either blood or crys- 
talloid cardioplegic solution causes prolonged myo- 
cyte membrane depolarization and associated 
changes in ionic balance including sodium influx and 
an increase in intracellular calcium by sodium- 
calcium exchange, increased calcium release from 
sarcoplasmic reticulum, and an influx of calcium 
through slow calcium channels. 2s Such alterations in 
ionic homeostasis also appear to play a role in the 
observed abnormalities in volume regulation with 
reperfusion and rewarming, especially since im- 
proved control of calcium transients during car- 
dioplegic arrest appears to attenuate myocyte swell- 
ing. 9 Thus myocardial edema may be primarily 
related to the hyperkalemia-induced membrane de- 
polarization and may not be a direct consequence of
the cardioplegia vehicle. 
j3-Adrenergic stimulation in the present study 
caused an increase in myocyte contractile function 
in normothermic control myocytes and in myocytes 
after hyperkalemic cardioplegic arrest. The contrac- 
tile function response to 13-adrenergic treatment, 
however, was blunted to a similar degree after 
cardioplegic arrest with both oxygenated crystalloid 
cardioplegia and oxygenated blood cardioplegia. 
Such reduced 13-adrenergic responsiveness with ei- 
ther cardioplegic solution may have clinical implica- 
tions, because treatment with/3-adrenergic agents is 
frequently necessary after prolonged hyperkalemic 
cardioplegic arrest. The/3-receptor uncoupling with 
subsequent dampened adenylyl cyclase activity that 
has been shown after hyperkalemic ardioplegic 
arrest probably contributes to the reduced /3-ad- 
renergic responsiveness observed. 29 Thus blood 
cardioplegia did not appear to be better than 
oxygenated crystalloid cardioplegia in enhancing 
the capacity of the myocyte to respond to an 
inotropic stimulus. 
This study examined contractile function after 
cardioplegic arrest with blood cardioplegia nd ox- 
ygenated crystalloid cardioplegia in an isolated myo- 
cyte model of hypothermic, hyperkalemic cardiople- 
gic arrest. An isolated myocyte model used in the 
present study allows for direct measurements of
contractile function without changes in loading con- 
ditions, neurohormonal activity, or alterations in 
coronary perfusion that could alter ventricular per- 
formance in vivo. Although the isolated myocyte 
model has some advantages over an in vivo prepa- 
ration, it has important limitations as well. An 
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isolated myocyte system allows for maximal solute 
diffusion capacity between the cytosol and extra- 
cellular space. This differs from an in vivo prepa- 
ration in which capillary diffusion distances are 
affected by coronary artery disease and hypertro- 
phy, and uniform temperature control and main- 
tenance are not achieved. Furthermore, cardio- 
plegia affects the entire myocard!um, which 
includes not only myocytes, but also endothelium, 
fibrocytes, and the interstitium, it is possible that 
a beneficial effect of blood cardioplegia on myo- 
cardial protection occurs at a site removed from 
the myocyteo For example, a recent in vivo canine 
model of cardiopulmonary bypass demonstrated 
superior protection of the microvascular endothe- 
lium by blood when compared with oxygenated 
crystall0id cardioplegia. 3° 
In summary, oxygenated crystalloid cardioplegia 
and oxygenated blood cardioplegia were equivalent 
in the preservation of contractile function and/3-ad- 
renergic responsiveness in an isolated myocyte 
model of hypothermic, hyperkalemic cardioplegic 
arrest. Moreover, disruption of myocyte volume 
regulation was similar after hyperkalemic ardiop!e- 
gic arrest with either blood or oxygenated crystalloid 
cardioplegia. This suggests that the effects of blood 
cardioplegia nd oxygenated crystalloid cardioplegia 
are equivalent with respect to contractile processes 
and volume regulation on the fundamental unit of 
the heart, the myocyte. If improved protection of 
myocyt e contractile processes exits, it must be oper- 
ative on other elements and mechanisms within the 
myocardium. 
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